Tests VK2735 for safety in adults with obesity
Tests the drug VK2735 against placebo in adults with obesity.
Plain-language title generated from the registry record
Registry title: A Phase 1 Study of VK2735 in Obese Adults Without Comorbidities
Key facts
- Where
- Lake Forest and Miami, United StatesSee the 2 sites
- Phase
- Phase 1
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 60 years old?
Source: NCT07838740, who can take part
Where in United States
- Lake ForestLake Forest, United StatesTaking people
- MiamiMiami, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Viking Therapeutics, Inc.
- Trial code
- NCT07838740
- Record updated
- 24 September 2026
- Original description
The goal of this Phase 1, randomized, double-blind, placebo-controlled study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of VK2735 in adults who are obese (BMI ≥ 30 kg/m2) without comorbidities.Read full original descriptionShow less
A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VK2735 Administration in Adults Who Are Obese (BMI ≥ 30 kg/m2) Without Comorbidities
The goal of this Phase 1, randomized, double-blind, placebo-controlled study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of VK2735 in adults who are obese (BMI ≥ 30 kg/m2) without comorbidities.
Inclusion: Must be capable of giving a signed informed consent form (ICF); Must be medically healthy, with no significant medical history, have no clinically significant abnormalities on physical examination at Screening and/or before administration of the initial dose of IP in the opinion of the study Investigator; BMI ≥ 30 kg/m2; Willing to comply with contraceptive requirements.
Exclusion: Any surgical or medical condition (active or chronic) that may interfere with IP distribution, metabolism, excretion or drug absorption; Any condition that might compromise safety or other endpoints in the study as judged by the Sponsor (or designee) or Investigator; History or presence of clinically significant acute or unstable cerebrovascular (stroke), hepatic, renal, gastrointestinal, pulmonary, immunological, endocrine, hematological, oncological, or central nervous disorder that in the opinion of the Investigator would pose a significant risk for the participant; Current or past diagnosis of diabetes mellitus (including type 1 and type 2, except gestational diabetes); Have a personal or family history of medullary thyroid carcinoma (MTC) or have multiple endocrine neoplasia syndrome type 2 (MEN-2); Participants with any level of disease or organ system dysfunction as identified during physical examination, medical history, or laboratory testing, as assessed by the Investigator; Alanine aminotransferase (ALT) level or aspartate transaminase (AST) level > 3.0 times the ULN for the reference range; Impaired renal function with estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73 m2 as measured at Screening.